Drug repositioning

Mehndiratta, Man Mohan; Wadhai, Swati Anil; Tyagi, B. K.; Gulati, Nitya; Sinha, Madhu

doi:10.1016/j.ijep.2016.09.002

Cited by 26 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Knowing that chemotherapy for schistosomiasis is still fragmentary; drug repurposing can be an alternative strategy to finding a cure for this acute disease. Drug repositioning involves investigating existing drugs and its application in treating non-related diseases for which they were not originally designed [117]. Although several researchers have studied various classes of drugs for anti-schistosomal effects, drugs used in treating cancers have also shown promising effects.…”

Section: Emerging Drugs In Fighting Schistoso-misismentioning

confidence: 99%

PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?

Aruleba

Adekiya

Oyinloye

et al. 2019

IDDT

View full text Add to dashboard Cite

Today schistosomiasis, caused mainly by the three major schistosome species (S. mansoni, S. haematobium and S. japonicum), has for many decades and still continues to be on a rapid and swift rise globally, claiming thousands of lives every year and leaving 800 million people at the risk of infection. Due to the high prevalence of this disease and the steady increase in the infection rates, praziquantel (PZQ) remains the only effective drug against this acute disease although it has no effect on the juvenile schistosome parasite. However, no significant approaches have been made in recent years in the discovery of new or alternative drugs and unfortunately, resistance to this drug has been reported in some parts of the world. Therefore, it is imperative to develop a new drug for this debilitating disease. In this review, a brief history of past, present, and new promising anti-schistosomal drugs is presented.

show abstract

Section: Emerging Drugs In Fighting Schistoso-misismentioning

confidence: 99%

PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?

Aruleba

Adekiya

Oyinloye

et al. 2019

IDDT

View full text Add to dashboard Cite

show abstract

“…Ashburn and Thor (2004) defined drug repositioning as the process of finding a new indication for a drug which has already been approved. This method has proved to be the preferred alternative strategy for the fast-moving discovery of drugs, since it is relatively cheaper and represents a minimum risk to patients due to the availability of previous pharmacological, safety and toxicological data (Mehndiratta et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Synergistic effect of sertraline and disulfiram against multidrug resistant bacteria as a new alternative to drug repositioning

Serafin

Bottega

Foletto

et al. 2020

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The repositioning of approved drugs is atopic of interest for the academy and the pharmaceutical industry. The synergistic combination of these drugs can be successful in the treatment of infections caused by resistant bacteria. This study aimed to assess the in vitro synergistic antibacterial activity of sertraline and disulfiram and their interaction with ciprofloxacin and sulfamethoxazole/trimethoprim. We determined the minimum inhibitory concentration, the minimum bactericidal concentration and the fractional inhibitory concentration index. Eighteen bacterial strains were used, being nine American Type Culture Collection reference strains and nine multidrug resistant clinical isolates. Synergy was detected between sertraline and disulfiram against a strain of Staphylococcus aureusATCC 25923 and a clinical isolate of S. aureus. When associated to sulfamethoxazole/trimethoprim and ciprofloxacin, sertraline and disulfiram showed eight synergistic events, which occurred against three different standard strains and two multidrug resistant clinical isolates. When the minimum bactericidal concentration was determined, the bactericidal activity of sertraline was enhanced with disulfiram. Our results suggest that these drugs, widely used to treat depression and chronic alcoholism, have antibacterial potential individually, in association, and combined with antimicrobials, what makes their repositioning a promising therapeutic alternative for the effective treatment of infections caused by multidrug resistant bacteria.

show abstract

“…Thus, drug repositioning was an alternative approach as therapeutic switching or drug repurposing for already marketed drug with less time consuming and less costly 16 . It has proved to be a preferred strategy for accelerated drug discovery as a relatively inexpensive pathway that carries minimal risk due to availability of previous pharmacological, safety and toxicology data 17 with many successful suggested studies in the literature 18 – 33 .…”

Section: Introductionmentioning

confidence: 99%

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

Ayoub

Mowaka

Safar

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Drug repositioning is a revolution breakthrough of drug discovery that presents outstanding privilege with already safer agents by scanning the existing candidates as therapeutic switching or repurposing for marketed drugs. Sitagliptin, vildagliptin, saxagliptin & linagliptin showed antioxidant and neurorestorative effects in previous studies linked to DPP-4 inhibition. Literature showed that gliptins did not cross the blood brain barrier (BBB) while omarigliptin was the first gliptin that crossed it successfully in the present work. LC-MS/MS determination of once-weekly anti-diabetic DPP-4 inhibitors; omarigliptin & trelagliptin in plasma and brain tissue was employed after 2 h of oral administration to rats. The brain/plasma concentration ratio was used to deduce the penetration power through the BBB. Results showed that only omarigliptin crossed the BBB due to its low molecular weight & lipophilic properties suggesting its repositioning as antiparkinsonian agent. The results of BBB crossing will be of interest for researchers interested in Parkinson’s disease. A novel intranasal formulation was developed using sodium lauryl sulphate surfactant to solubilize the lipophilic omarigliptin with penetration enhancing & antimicrobial properties. Intranasal administration showed enhanced brain/plasma ratio by 3.3 folds compared to the oral group accompanied with 2.6 folds increase in brain glucagon-like peptide-1 concentration compared to the control group.

show abstract

Drug repositioning

Cited by 26 publications

References 29 publications

PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?

PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?

Synergistic effect of sertraline and disulfiram against multidrug resistant bacteria as a new alternative to drug repositioning

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

Contact Info

Product

Resources

About